Results 11 to 20 of about 25,148 (309)

Drug discovery of sclerostin inhibitors

Acta Pharmaceutica Sinica B, 2022
Sclerostin, a protein secreted from osteocytes, negatively regulates the WNT signaling pathway by binding to the LRP5/6 co-receptors and further inhibits bone formation and promotes bone resorption.
Meiheng Sun, Huan Xiao, Ge ZHANG
exaly   +5 more sources

Macrophagic Sclerostin Loop2‐ApoER2 Interaction Required by Sclerostin for Cardiovascular Protective Action [PDF]

Advanced Science
Therapeutic antibody against sclerostin loop2 promoted bone formation in postmenopausal osteoporosis but caused severe cardiovascular events in clinical applications.
Luyao Wang, Xiaohui Tao, Ning Zhang, Xin Yang, Hewen Jiang, Xiaofei Li, Shenghang Wang, Shijian Ding, Sifan Yu, Huarui Zhang, Yihao Zhang, Nanxi Li, Haitian Li, Zhanghao Li, Xiaoxin Wen, Meiheng Sun, Chuanxin Zhong, Jin Liu, Yuanyuan Yu, Xianghang Luo, Tao Zhang, Shu Zhang, Péter Ferdinandy, Yu Huang, Daqing Ma, Aiping Lu, Baoting Zhang, Ge Zhang   +27 more
doaj   +3 more sources

B4GALNT3 regulates glycosylation of sclerostin and bone massResearch in context

EBioMedicine, 2023
Summary: Background: Global sclerostin inhibition reduces fracture risk efficiently but has been associated with cardiovascular side effects. The strongest genetic signal for circulating sclerostin is in the B4GALNT3 gene region, but the causal gene is ...
Sofia Movérare-Skrtic, Jakob Voelkl, Karin H. Nilsson, Maria Nethander, Trang Thi Doan Luong, Ioana Alesutan, Lei Li, Jianyao Wu, Karin Horkeby, Marie K. Lagerquist, Antti Koskela, Juha Tuukkanen, Jon H. Tobias, Ulf H. Lerner, Petra Henning, Claes Ohlsson   +15 more
doaj   +2 more sources

Cardioprotective function of sclerostin by reducing calcium deposition, proliferation, and apoptosis in human vascular smooth muscle cells

Cardiovascular Diabetology, 2023
Background Sclerostin is an inhibitor of the Wnt/b-catenin pathway, which regulates bone formation, and can be expressed in vascular smooth muscle cells (VSMCs).
Sheila González-Salvatierra, Cristina García-Fontana, Jesus Lacal, Francisco Andújar-Vera, Luis Martínez-Heredia, Raquel Sanabria-de la Torre, María Ferrer-Millán, Enrique Moratalla-Aranda, Manuel Muñoz-Torres, Beatriz García-Fontana   +9 more
doaj   +2 more sources

Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin-mediated antagonism of Wnt/LRP6 signaling. [PDF]

PLoS ONE, 2013
Sclerosteosis is a rare high bone mass disease that is caused by inactivating mutations in the SOST gene. Its gene product, Sclerostin, is a key negative regulator of bone formation and might therefore serve as a target for the anabolic treatment of ...
Maarten van Dinther, Juan Zhang, Stella E Weidauer, Verena Boschert, Eva-Maria Muth, Achim Knappik, David J J de Gorter, Puck B van Kasteren, Christian Frisch, Thomas D Mueller, Peter ten Dijke   +10 more
doaj   +6 more sources

Sclerostin and Cardiovascular Disease

Current Osteoporosis Reports, 2023
The role of wnt signalling in atherogenesis raises the possibility that the wnt inhibitor, sclerostin, provides a natural defence to this process, and that anti-sclerostin antibodies might increase the risk of atherosclerosis and associated conditions ...
J. Tobias
semanticscholar   +4 more sources

Sclerostin regulation: a promising therapy for periodontitis by modulating alveolar bone

Chinese Medical Journal, 2020
. Periodontitis is one of the most prevalent epidemics affecting human health and life recently, and exploration of the pathogenesis and treatment of periodontitis has been valued by scholars.
Tian-Jiao Li, Rui Wang, Qin-Yang Li, Chun-Yu Li, Li Jiang, Li-Shao Guo   +5 more
doaj   +2 more sources

Adipocytic sclerostin loop3-LRP4 interaction required by sclerostin to impair whole-body lipid and glucose metabolism [PDF]

Nature Communications
Sclerostin, which has three loops, inhibits bone formation and impairs whole-body lipid and glucose metabolism. The marketed therapeutic sclerostin antibody for postmenopausal osteoporosis (POP) mainly targeting loop2 promotes bone formation and improves
Hewen Jiang, Xiaohui Tao, Sifan Yu, Yihao Zhang, Yuan Ma, Nanxi Li, Shenghang Wang, Ning Zhang, Xin Yang, Shijian Ding, Chuanxin Zhong, Haitian Li, Zhanghao Li, Xiaoxin Wen, Huarui Zhang, Zefeng Chen, Meiheng Sun, Hang Luo, Meishen Ren, Chongguang Lei, Yuanyuan Yu, Jin Liu, Zongkang Zhang, Aiping Lyu, Hui Sheng, Dijie Li, Luyao Wang, Ge Zhang, Bao-Ting Zhang   +28 more
doaj   +2 more sources

Sclerostin inhibition in rare bone diseases: Molecular understanding and therapeutic perspectives

Journal of Orthopaedic Translation
Sclerostin emerges as a novel target for bone anabolic therapy in bone diseases. Osteogenesis imperfecta (OI) and X-linked hypophosphatemia (XLH) are rare bone diseases in which therapeutic potential of sclerostin inhibition cannot be ignored.
Tao Xiaohui, Luyao Wang, Xin Yang, Hewen Jiang, Ning Zhang, Huarui Zhang, Dijie Li, Xiaofei Li, Yihao Zhang, Shenghang Wang, Chuanxin Zhong, Sifan Yu, Meishen Ren, Meiheng Sun, Nanxi Li, Tienan Chen, Yuan Ma, Fangfei Li, Jin Liu, Yuanyuan Yu, Hua Yue, Zhenlin Zhang, Ge Zhang   +22 more
doaj   +2 more sources

Sclerostin is a promising therapeutic target for oral inflammation and regenerative dentistry

Journal of Translational Medicine, 2022
Sclerostin is the protein product of the SOST gene and is known for its inhibitory effects on bone formation. The monoclonal antibody against sclerostin has been approved as a novel treatment method for osteoporosis.
Chufang Liao, Shanshan Liang, Yining Wang, Ting Zhong, Xiangning Liu   +4 more
doaj   +2 more sources